ICAP Ocean Tomo Retained by Childrens Hospital Los Angeles/California Institute of Technology to Sell Patent Portfolio Relating to Non-Invasive Substance Detection Technology

CHICAGO--(Business Wire)--
ICAP Ocean Tomo announced today it has been retained to sell a patent portfolio
for the Childrens Hospital Los Angeles and the California Institute of
Technology (CHLA/CALTECH). The portfolio contains 19 issued patents and patent
applications relating to non-invasive substance detection. The sale of this
technology will take place November 30, 2009.

The portfolio includes nine patents that can be classified into two distinct
technologies: a Non-invasive Blood Glucose Monitor, and the Assessment of the
Blood-brain barrier functions and detection of substances. The patented
Non-invasive Substance Detection Technology addresses many unmet needs for a
large population of patients and healthcare providers. This technology, using
analysis of the Raman Spectrum generated by the incidence of a laser beam on the
anterior chamber of the eye, determines a person`s blood sugar level. For the
first time the patents pertaining to the Blood-brain barrier functions and
detection allows the direct measurement of substance levels within the brain and
cerebrospinal fluid.

"We are excited to have ICAP Ocean Tomo engaged in the process of licensing this
unique technology portfolio," said Dr. Mark Borchert, M.D., head of the Division
of Ophthalmology at Childrens Hospital Los Angeles, director of the Eye Birth
Defects Institute and Eye Technology Institute in the Vision Center of Childrens
Hospital and associate professor of clinical ophthalmology and neurology at the
Keck School of Medicine of the University of Southern California. "Introduction
of a non-invasive glucose detection technology, as seen in this portfolio,
offers many advantages to both doctors and patients, and is a significant step
forward for the healthcare and biotech industries."

Advantages of the non-invasive substance detection technology include:

* Diabetes management providing tighter glycemic control without the use of
consumable items, providing a better patient compliance rate
* Large market potential, with assets covering the use of the invention across
diagnostics, drug trials, space exploration and alcohol detection
* A non-invasive, non-infectious detection system, allowing for assessment
requiring no direct contact with body fluids

"The Childrens Hospital/Caltech portfolio has so much market potential," said DJ
Nag, Vice President, ICAP Ocean Tomo. "We are excited about the opportunity to
broker this sale, providing a great asset to the biotech industry, which has
historically been an underserved market."

For information regarding this portfolio please contact ICAP Ocean Tomo at
1-866-779-8363 or patent.brokerage@us.icap.com

About ICAP Ocean Tomo LLC

ICAP Ocean Tomo, a division of ICAP, is the recognized global leader in
intellectual property brokerage. We leverage the talents of experienced
intellectual property monetization professionals to match buyers and sellers for
the sale of patents and other intellectual property assets. With multiple
transaction platforms and unparalleled industry knowledge and expertise, ICAP
Ocean Tomo is uniquely positioned to handle the IP monetization needs of any
client.

About Childrens Hospital Los Angeles

Founded in 1901, Childrens Hospital Los Angeles has been treating the most
seriously ill and injured children in Los Angeles for more than a century, and
it is acknowledged throughout the United States and around the world for its
leadership in pediatric and adolescent health. Childrens Hospital is one of
America`s premier teaching hospitals, affiliated with the Keck School of
Medicine of the University of Southern California since 1932. The Saban Research
Institute of Childrens Hospital Los Angeles is among the largest and most
productive pediatric research facilities in the United States. For more
information on Childrens Hospital Los Angeles, visit Childrens Hospital Los
Angeles.

About California Institute of Technology

The mission of the California Institute of Technology is to expand human
knowledge and benefit society through research integrated with education.
Caltech investigates the most challenging, fundamental problems in science and
technology in a singularly collegial and interdisciplinary atmosphere. Founded
in 1995, Caltech`s Office of Technology Transfer (OTT) works to effectively
commercialize technology developed at Caltech and the Jet Propulsion Laboratory
(JPL). Specifically, OTT assists the faculty with intellectual property,
evaluates inventions, manages the Caltech/JPL patent portfolio, negotiates
technology licenses and assists entrepreneurs with the creation of startups. For
more information, visit California Institute of Technology.

ICAP Ocean Tomo LLC
Cali Munoz
312-377-4831
cmunoz@oceantomo.com

Copyright Business Wire 2009